Direct Cardiac Reprogramming for Cardiovascular Regeneration and Differentiation
-
- Sadahiro Taketaro
- Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
-
- Ieda Masaki
- Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
Search this article
Abstract
<p>Cardiovascular disease is the leading cause of death worldwide. Cardiomyocytes have limited regenerative capacity; consequently, regenerative therapies are in high demand. There are currently several potential strategies for heart regeneration, with one approach involving in situ generation of new cardiomyocytes from endogenous cell sources. Direct cardiac reprogramming has emerged as a novel therapeutic approach to regenerating the damaged heart by directly converting endogenous cardiac fibroblasts into cardiomyocyte-like cells. Following our first report of direct cardiac reprogramming, significant advances have elucidated the molecular mechanisms associated with cardiac reprogramming. These advances have also improved cardiac-reprogramming efficiency by enabling direct in vivo cardiac reprogramming. Moreover, progress has been made in cardiac reprogramming of human fibroblasts. Although basic research has supported substantial progress in this field, numerous challenges remain in terms of clinical application. Here, we review the current state of cardiac reprogramming as a new technology for understanding and treating cardiovascular diseases.</p>
Journal
-
- The Keio Journal of Medicine
-
The Keio Journal of Medicine 69 (3), 49-58, 2020
The Keio Journal of Medicine
